EUVIMEDEUVIMED entdecken
Crossref

Characterization of kinase inhibitors targeting MAP tau hyperphosphorylation as potential therapeutic agents for Alzheimer’s disease

Matilde Ercole, Jack A. Tuszynski

Journal of Multiscale Neuroscience · 27.06.2026 · 5 (2) · 80-93

DOI: 10.56280/1753809378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Multiscale Neuroscience, online erschienen am 27.06.2026. Verfasst von Matilde Ercole und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder characterized by tau hyperphosphorylation, which contributes to neurofibrillary tangle formation and neuronal loss. Multiple kinases are involved in this process making them potential therapeutic targets. However, the identification of selective inhibitors with favourable pharmacokinetic properties and adequate brain penetration remains a challenge. In this study, thirteen tau-related kinases were prioritized according to the number of predicted tau serine phosphorylation sites identified using a percentile-based filtering approach. Known inhibitors for each kinase were evaluated using Boltz-2 AI-based docking software and predicted binding affinity likelihood (BAL) scores and IC₅₀-like values were combined to rank inhibitors within each kinase-specific set. The selected compounds were subsequently evaluated using SwissADME pharmacokinetic software, focusing on blood-brain barrier permeability, gastrointestinal absorption, P-glycoprotein interaction, and compliance with Lipinski’s rule of five. Molecular selectivity was estimated using experimentally determined IC₅₀ data retrieved from ChEMBL, while protein brain expression and protein–protein interaction data were obtained from the Human Protein Atlas and STRING databases. The results identified kinase inhibitors with favourable predicted pharmacokinetic properties and varying degrees of target selectivity. Together, these analyses provide a framework for prioritizing kinase inhibitors for further investigation and experimental validation in the context of future AD therapy development.

Zitieren

APA

Ercole, M., & Tuszynski, J. A. (2026). Characterization of kinase inhibitors targeting MAP tau hyperphosphorylation as potential therapeutic agents for Alzheimer’s disease. Journal of Multiscale Neuroscience, 5(2), 80-93. https://doi.org/10.56280/1753809378

Vancouver

Ercole M, Tuszynski JA. Characterization of kinase inhibitors targeting MAP tau hyperphosphorylation as potential therapeutic agents for Alzheimer’s disease. Journal of Multiscale Neuroscience. 2026;5(2):80-93. doi:10.56280/1753809378

BibTeX
@article{Ercole2026,
  author = {Ercole, Matilde and Tuszynski, Jack A.},
  title = {Characterization of kinase inhibitors targeting MAP tau hyperphosphorylation as potential therapeutic agents for Alzheimer’s disease},
  journal = {Journal of Multiscale Neuroscience},
  year = {2026},
  volume = {5},
  number = {2},
  pages = {80--93},
  doi = {10.56280/1753809378}
}
Kostenlos starten →